| Literature DB >> 24885622 |
Peiling Yap1, Jürg Utzinger, Jan Hattendorf, Peter Steinmann.
Abstract
BACKGROUND: The relationship between nutrition and soil-transmitted helminthiasis is complex and warrants further investigation. We conducted a systematic review examining the influence of nutrition on infection and re-infection with soil-transmitted helminths (i.e. Ascaris lumbricoides, hookworm, Trichuris trichiura and Strongyloides stercoralis) in humans. Emphasis was placed on the use of nutritional supplementation, alongside anthelminthic treatment, to prevent re-infection with soil-transmitted helminths.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24885622 PMCID: PMC4032457 DOI: 10.1186/1756-3305-7-229
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Figure 1Conceptual framework underpinning this systematic review. The black arrows indicate research gaps in the understanding of the interactions between soil-transmitted helminth infections and undernutrition.
Figure 2Search strategy for the identification of studies examining the influence of nutrition on (re-)infection with soil-transmitted helminths in humans.
Summary of findings from 15 studies meeting the inclusion criteria of the systematic review pertaining to undernutrition and re-infection with soil-transmitted helminths
| 1) Nga | 6- to 8-year-old children | i) Multi-micronutrient biscuits fortified with iron, zinc, iodine and vitamin A given on 5 days per week for 4 months. Albendazole (400 mg, single dose) at baseline | |
| ii) Multi-micronutrient biscuits and placebo, identical looking to albendazole | |||
| iii) Non-fortified, identical looking biscuits and albendazole at baseline | |||
| iv) Non-fortified, identical looking biscuits and albendazole placebo | |||
| 2) Nga | 6- to 8-year-old children | i) Multi-micronutrient biscuits fortified with iron, zinc, iodine and vitamin A given on 5 days per week for 4 months. Albendazole (400 mg, single dose) at baseline | |
| ii) Multi-micronutrient biscuits and placebo, identical looking to albendazole | |||
| iii) Non-fortified, identical looking biscuits and albendazole at baseline | |||
| iv) Non-fortified, identical looking biscuits and albendazole placebo | |||
| 3) Nchito | 7- to 15-year-old children | i) Albendazole (400 mg) given to all study participants on 2 consecutive days at baseline | |
| ii) Multi-micronutrient tablet fortified with vitamin A, B1, B2, B6, B12, C, D and E, niacin, folic acid, zinc, iodine, copper and selenium every school day for 10 months. Ferrous dextran tablet (equivalent to 60 mg of elemental iron) every school day for 10 months | ii) Moderate-to-weak positive effect on the reduction of the infection intensity of | ||
| iii) Multi-micronutrient tablet and placebo iron tablet | |||
| iv) Placebo multi-micronutrient tablet and ferrous dextran tablet | |||
| v) Placebo multi-micronutrient tablet and placebo iron tablet | |||
| 4) Long | 6- to 15-month-old children | i) Vitamin A (given as 20,000 IU of retinol for children <1 year and 45,000 IU for children >1 year) every 2 months for 1 year. Zinc methionine (equivalent to 20 mg of elemental zinc) | |
| ii) Zinc methionine only | |||
| iii) Vitamin A only | |||
| iv) Placebo | |||
| 5) Long | 5- to 15-month-old children | i) Vitamin A (given as 20,000 IU of retinol for children <1 year and 45,000 IU for children >1 year) every 2 months for 15 months | |
| ii) Placebo | |||
| 6) Olsen | 8- to 18-year-old children | i) Albendazole (600 mg, single dose) given to all children at baseline and 4 weeks after baseline (600 mg, single dose) if child was still infected | |
| ii) Multi-micronutrient tablet fortified with vitamin A, B1, B2, B6, B12, C, D and E, niacin, folic acid, zinc, iodine, copper, iron and selenium every school day for 11 months | ii) For children taking 'multi-micronutrients’ | ||
| iii) Placebo, identical looking to the multi-micronutrient tablet | |||
| 7) Olsen | 4- to 15-year-old children (n = 200) and 16- to 63-year-old adolescents and adults (n = 129) | i) Albendazole (400 mg, once a day for 3 consecutive days) at baseline for all individuals and if any individual was still infected between 3 and 6 months after baseline, re-treatment (400 mg, single dose) was given | |
| ii) Ferrous dextran tablet (equivalent to 60 mg of elemental iron) twice weekly for 12 months | ii) For adolescents/adults taking 'iron’ | ||
| iii) Placebo identical looking to the ferrous dextran tablet | |||
| 8) Grazioso | 65- to 95-month-old children | i) Mebendazole (100 mg twice daily for 3 days) at baseline for all individuals | |
| ii) Tablet containing zinc (10 mg) and vitamin A, E, C, B6, B12 and D, folic acid, thiamin, riboflavin, niacinamide, pantothenic acid, iron, copper, iodine, selenium, chromium and magnesium given on every school day for 120–150 days | |||
| iii) Different colour-coded tablets, containing all the micronutrients, except for zinc, found in the intervention tablet | |||
| 9) Halpenny | <5-year-old children | i) Cycle 1: albendazole (200–400 mg depending on age, single dose) to all children >12 months at baseline. Children followed up for 9 months | |
| ii) Cycle 2: albendazole (200–400 mg depending on age, single dose) to all children >12 months at baseline. Children who remained infected with at least 1 soil-transmitted helminth were given another single dose of albendazole. Children followed up for 6 months | |||
| 10) Hesham Al-Mekhlafi | 7- to 12-year-old children | i) Albendazole (400 mg, once a day for 3 consecutive days) for all children at baseline. Children followed for 6 months to investigate predictors of re-infection | |
| 11) Payne | 12- to 60-month-old children | i) One-off supplementation with vitamin A (60 mg retinol) given by the Ministry of Health | |
| ii) Albendazole (400 mg, single dose) for all children at baseline. Children were followed at 3 and 5 months post-treatment | |||
| 12) Saldiva | 1- to 10-year-old children | i) Mebendazole (triple doses at baseline and repeated 15 days after). Children were followed at 1 year post-treatment | |
| 13) Hagel | 6- to 11-year-old children | i) Oxantel/pyrantel (20 mg/kg) monthly for 12 months for all children. Children were followed at 8 months after the 12 months of treatment | |
| 14) Kightlinger | 4- to 10-year-old children | i) Mebendazole (500 mg, single dose) was given to all children at baseline. Children were followed at the end of 12 months, when they were given pyrantel pamoate (11 mg/kg) and 48-hour worm expulsions were performed | |
| 15) Hagel | 6- to 11-year-old children | i) Oxantel/pyrantel (20 mg/kg) monthly for 12 months for all children. Children were followed at the end of the 12 months of treatment | |
aCP, cohort prospective; RCT, randomised controlled trial.
bA, A. lumbricoides; H, hookworm; T, T. trichiura.
GRADE evidence profile (EP) for the 15 studies included in the systematic review
| | ||||||
|---|---|---|---|---|---|---|
| 1) Nga | No serious limitation | No serious inconsistency | No serious indirectness | No serious imprecision | None detected | ⊕ ⊕ ⊕⊕ High |
| 2) Nga | No serious limitation | No serious inconsistency | No serious indirectness | No serious imprecision | None detected | ⊕ ⊕ ⊕ ⊕ High |
| 3) Nchito | Serious limitation (sample size used for analysis was smaller than that required for statistical significance; mean number of supplementation tablets taken was only 50% of tablets provided) | Serious inconsistency (administration of albendazole at baseline was not stated under study design but was mentioned under results) | No serious indirectness | No serious imprecision | Serious risk of bias (47% of children were lost to follow-up; method of recruitment and inclusion/exclusion criteria were not mentioned) | ⊕ ⊕ ◯ ◯ Low |
| 4) Long | No serious limitation | No serious inconsistency | No serious indirectness | No serious imprecision | None detected | ⊕ ⊕ ⊕ ⊕ High |
| 5) Long | No serious limitation | No serious inconsistency | No serious indirectness | No serious imprecision | None detected | ⊕ ⊕ ⊕ ⊕ High |
| 6) Olsen | Serious limitation (compliance rates for the multi-micronutrient tablet and placebo were low at 46%) | Serious inconsistency (the allocation of anthelminthic treatment and placebo was not clear) | No serious indirectness | No serious imprecision | Serious risk of bias (number of stool samples collected for each child varied) | ⊕ ⊕ ◯ ◯ Low |
| 7) Olsen | No serious limitation | Serious inconsistency (reporting of results was not consistent for all helminth species) | No serious indirectness | No serious imprecision | Serious risk of bias (method of recruitment and blinding procedures not mentioned; number of stool samples collected varied at each follow-up) | ⊕ ⊕ ◯ ◯ Low |
| 8) Grazioso | No serious limitation | Serious inconsistency (data reported under abstract is different from that found in the results section) | No serious indirectness | Serious imprecision (stratification of results according to soil-transmitted helminth species was not performed) | Very serious risk of bias (number of intervention days not clear; reporting of primary outcome measures were not complete) | ⊕ ◯ ◯ ◯ Very low |
| 9) Halpenny | Serious limitation (compliance rate for albendazole at both treatment cycles was low at 48%) | No serious inconsistency | No serious indirectness | No serious imprecision | None detected | ⊕ ⊕ ◯ ◯ Low |
| 10) Hesham Al-Mekhlafi | No serious limitation | Serious inconsistency (reporting of sample size was not consistent throughout the study) | No serious indirectness | Serious imprecision (stratification of results according to soil-transmitted helminth species was not performed) | None detected | ⊕ ◯ ◯ ◯ Very low |
| 11) Payne | No serious limitation | No serious inconsistency | No serious indirectness | No serious imprecision | Serious risk of bias (vitamin A supplemented children came from families with significantly higher income and latrine access than the non-supplemented children; 34% children were lost to follow-up) | ⊕ ⊕ ◯ ◯ Low |
| 12) Saldiva | No serious limitation | Serious inconsistency (stratification of undernourished and eutrophic children not clear) | No serious indirectness | Serious imprecision (stratification of results according to soil-transmitted helminth species was not performed) | None detected | ⊕ ◯ ◯ ◯ Very low |
| 13) Hagel | No serious limitation | No serious inconsistency | No serious indirectness | No serious imprecision | Serious risk of bias (poverty level as a confounding factor was not taken into account during data analysis) | ⊕ ◯ ◯ ◯ Very low |
| 14) Kightlinger | No serious limitation | Serious inconsistency (number of children included for analysis varied for different outcome measures) | No serious indirectness | No serious imprecision | Serious risk of bias (about 41% children were lost to follow-up) | ⊕ ◯ ◯ ◯ Very low |
| 15) Hagel | No serious limitation | No serious inconsistency | No serious indirectness | No serious imprecision | None detected | ⊕ ⊕ ◯ ◯ Low |
Figure 3Meta-analysis examining the association of nutritional supplementation/host’s natural nutrition status with (A), (B), hookworm (C) and soil-transmitted helminths combined (D) (Note: no data were identified for ).